A recent cohort recruiting 225,090 individuals with Crohn’s disease and 188,420 with ulcerative colitis showed that patients treated with anti-TNF agents were less likely to develop colorectal cancer (Alkhayyat et al., 2021). This evidence concerns the gene TNF and Crohn disease.